583 results about "Metformin" patented technology

Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.

A method for treating a patient using an antidiabetic drug, said method comprising administering to the patient a high dose of the antidiabetic drug wherein said antidiabetic drug exhibits one or more dose proportional pharmacokinetic parameters is described.

The subject invention provides compositions and methods for treating diabetes in patients. In a preferred embodiment, the invention provides compositions methods for treating diabetes and / or preventing or alleviating complications associated with diabetes. Specifically exemplified herein is the concurrent administration of a cysteamine compound with at least one additional therapeutic agent to prevent and / or treat diabetes as well as prevent and / or treat complications associated with diabetes. In a preferred embodiment, oral administration of cysteamine hydrochloride with Metformin to a patient diagnosed with diabetes can substantially regulate the patient's glucose metabolism and insulin sensitivity.

The subject invention provides compositions and methods for treating diabetes in patients. In a preferred embodiment, the invention provides compositions methods for treating diabetes and / or preventing or alleviating complications associated with diabetes. Specifically exemplified herein is the concurrent administration of a cysteamine compound with at least one additional therapeutic agent to prevent and / or treat diabetes as well as prevent and / or treat complications associated with diabetes. In a preferred embodiment, oral administration of cysteamine hydrochloride with Metformin to a patient diagnosed with diabetes can substantially regulate the patient's glucose metabolism and insulin sensitivity.

Described herein is a compound of Formula I, which is the metformin salt of the naturally occurring endogenous biological compound, (R)-(+) α lipoic acid, pharmaceutical compositions containing the compound of Formula I, and methods of treatment of diabetes or diabetic complications with the compound of Formula I.

Sustained release pharmaceutical formulations comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof are disclosed. The formulations provide therapeutic plasma levels of the antihyperglycemic drug to a human patient over a 24 hour period after administration.

The invention provides sustained release formulations of metformin or a pharmaceutically acceptable salt thereof, and methods of treating diabetes by administering to a patient a therapeutically effective amount of a sustained release formulation of metformin or a pharmaceutically acceptable salt thereof.

A metformin-cysteine prodrug. It is believed that the prodrug of the present invention will transport in the LAT1 and LAT2 transporter system. Because the LAT1 and LAT2 transporters are important and effective transporters of amino acids in both the small intestine and colon, it is believed that the LAT-transportable prodrugs of the present invention will be effectively absorbed both in small intestine and in the colon. The increased absorption window provided by the present invention should result in highly sustained plasma concentrations of metformin, thereby increasing the effectiveness of the medication and allowing for a single daily dose.

Solid oral dosage formulations, such as tablet, mini-tab, multiparticulates or osmotic delivery systems, are coated with a mucoadhesive polymeric coating or formed of a mucoadhesive polymer to increase oral bioavailability of Biopharmaceutical Classification System (BCS) Class I drugs. Representative BCS I drugs include valacyclovir, gabapentin, furosemide, levodopa, metformin, and ranitidine HCl. The inclusion of mucoadhesives in the solid oral dosage form brings the dosage form into close proximity with the target epithelium and facilitates diffusion of drug into intestinal tissue. The mucoadhesive polymer may be either dispersed in the matrix of the tablet or applied as a direct compressed coating to the solid oral dosage form. Preferred mucoadhesive polymers include poly(adipic)anhydride “P(AA)” and poly(fumaric-co-sebacic)anhydride “P(FA:SA)”. Other preferred mucoadhesive polymers include non-erodable polymers such as DOPA-maleic anhydride co polymer; isopthalic anhydride polymer; DOPA-methacrylate polymers; and DOPA-cellulosic based polymers.

A composition which includes a salt of metformin and the use of the composition for treatment of or use in prediabetes, diabetes, lowering triglycerides and / or other conditions in mammals.

A pharmaceutical composition in the form of tablets constitutes an orally administered, controlled drug delivery system that will provide increased retention time of the device in the stomach over conventional dosage forms and release metformin or its pharmaceutically acceptable salt in a controllable manner, and further that is easy and inexpensive to manufacture.

Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

A pharmaceutical composition comprising a solid unit dosage form comprising: one or more of pharmaceutically active ingredients selected from valacyclovir, olanzapine, voriconazole, topotecan, artesunate, amodiaquine, guggulosterone, ramipril, telmisartan, tibolone, atorvastatin, simvastatin, amlodipine, ezetimibe, fenofibrate, tacrolimus, valgancyclovir, valsartan, clopidrogel, estradiol, trenbolone, efavirenz, metformin, pseudoephedrine, verapamil, felodipine, valproic acid / sodium valproate, mesalamine, hydrochlorothiazide, levosulpiride, nelfinavir, cefixime and cefpodoxime proxetil in combination with a water insoluble polymer and / or a water soluble polymer. Methods for making the pharmaceutical composition are also disclosed.

The invention discloses a metformin hydrochloride enteric-coated sustained release tablet which is prepared by enteric coating the metformin hydrochloride sustained release tablet. Compared with the prior art, the sustained release tablet integrates with the enteric coating technology to prepare a new form of the metformin hydrochloride enteric-coated sustained release tablet. By using the enteric coating technology, the metformin hydrochloride does not disintegrate in the stomach or stimulate the gastric mucosa, and the adverse reaction of nausea, stomachache and diarrhea caused by medicine taking can be avoided; meanwhile, the metformin hydrochloride is prevented from being damaged by gastric juice, and the bioavailability is improved. The product is a sustained release preparation, the medicine can stably release in vivo, the effective blood concentration can be maintained for a long time, the toxic and side effects caused by over-high blood concentration in a short time are avoided, the medicine taking frequency is decreased, and the patient compliance is improved as well.

The invention discloses a preparation method of metformin hydrochloride. The preparation method is characterized by using dicyandiamide and dimethylamine hydrochloride as raw materials, feeding the materials in a mole ratio of (1:1)-(1:1.2), using N,N-dimethylacetamide or dimethyl sulfoxide 2-4 times dicyandiamide by weight as a solvent, and reacting for 4-8 hours at 140+ / -5 DEG C to prepare a crude metformin hydrochloride product; recrystallizing the crude product with ethanol, regulating the pH value to be 5-6, decoloring the crystal, cooling the crystal to minus 10-0 DEG C while stirring, precipitating the crystal, obtaining a refined metformin hydrochloride product through filtering and drying, and recovering the solvent from filtrate. The qualified product has yield of 80-85% and high purity. The preparation method has the advantages that as the selected reaction solvent has a relatively high boiling point, the recovery rate of the solvent is high; the phenomenon of material surging can be effectively avoided, so that the preparation method has the advantages of mild reaction conditions, simplicity in operation and high safety.

Metformin salts of lipophilic acids, their pharmaceutical formulations, and methods of administrating the metformin salts for the treatment of hyperglycemia.

Described are pharmaceutical compositions comprising bupropion, metformin, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective amount of bupropion and metformin. In certain embodiments, an aforementioned method is practiced in conjunction or tandem with a medical procedure or the use of a medical device or both.

The invention relates to a composition containing repaglinide and metformin hydrochloride and a preparation method thereof, belonging to the technical field of medicines. The composition containing repaglinide and metformin hydrochloride consists of repaglinide, metformin hydrochloride, a filling agent, a disintegrating agent, a bonding agent, a latent solvent and a lubricant, wherein the repaglinide is added into the metformin hydrochloride and auxiliary materials in the form of aqueous solution for wet granulation. The preparation method has the advantages of simple and efficient process, small using quantity of auxiliary materials, capability of solving the problem of poor content uniformity caused by small using amount of the repaglinide and increase in the dissolution rate; and moreover, a preparation has a smaller unit quantity and can be applied to industrial mass production.

The invention relates to field of natural medicine and medicinal chemistry, in particular to novel pentacyclic triterpene and melbine salt I of the derivative thereof. The salt compound can be used for preparing medicaments curing diabetes mellitus and complicating disease thereof, cerebral ischemia, angiocardiopathy, atherosclerosis, hepatitis, fatty liver and metabolic syndrome or tumour, descendens blood fat drugs and anti-obesity drugs. The invention also relates to the preparation method of the salt compound.

Disclosed herein is a method for treating a tumor in a subject in need thereof comprising administering an enhancing amount of metformin and a reduced amount of one or more chemotherapeutic agents. One example of an enhancing amount of metformin is about 250 mg / day. Also disclosed is a Untreated method for preventing cancer or delaying the recurrence of cancer in a subject comprising administering an effective amount of metformin to the subject. In one example of such a method, the amount of metformin is about 75 mg / day. Also disclosed is a composition comprising an enhancing amount of metformin, and a reduced amount of one or more chemotherapeutic agents and a pharmaceutically acceptable carrier. Kits comprising metformin and one or more chemotherapeutic agents are also disclosed.

Described are pharmaceutical compositions comprising topiramate, phentermine, and metformin, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective amount of topiramate, phentermine, and metformin. In certain embodiments, an aforementioned method is practiced in conjunction or tandem with a medical procedure or the use of a medical device or both.

A co-crystal composition comprised of Quercetin and at least one antidiabetic agent acts as a combination drug having unique physical properties and biological activity, which differ from both Quercetin in pure form and the at least one antidiabetic agent in pure form. The co-crystal composition may comprise quercetin and metformin. The co-crystals of quercetin and metformin may be prepared by grinding the compounds, and used in pharmaceutical compositions comprising these co-crystals. Co-crystal compositions of quercetin and Metformin may be used in combination with other anti-diabetic agents, including DPP-IV inhibitors.

The present invention relates to an extended release dosage form of highly water-soluble antidiabetic drug metformin or its pharmaceutically acceptable salts. This invention also relates to methods for preparing the extended release dosage forms of metformin or its pharmaceutically acceptable salts.

The present invention is directed to a liquid formulation of metformin or its pharmaceutically acceptable salts thereof. The liquid pharmaceutical composition comprises a therapeutically effective amount of metformin or its pharmaceutically acceptable salt, in a liquid carrier, which may also include a sweetener that does not increase the blood glucose level of a subject after ingestion thereof. In one embodiment, it may also include alkyl hydroxyethylcellulose, and / or a polyhydroxy alcohol. In another embodiment, the carrier may contain a sweetener, mineral acid, and bicarbonate salt maintained at a pH of 4.0 to 9.0. It is useful for treating hyperglycemia and diabetes.

The invention provides a metformin hydrochloride controlled-release tablet, which comprises a metformin hydrochloride controlled-release tablet with effective dose and pharmaceutical accessories and is characterized in that the metformin hydrochloride controlled-release tablet uses the common tabletting, and the controlled-release effect is controlled by totally depending on the film coating technique. The coating adopted by the invention is a releasing system comprising the prescription which can cause the medicine to reach release degree standard in vitro. The preparation method in the invention is simple and convenient; the process conditions are easy to control and suitable for batch production, can use conventional production equipment in pharmaceutical industries for economically and conveniently producing the metformin hydrochloride controlled-release tablet on a large scale, can effectively and stably cause the release degree of the metformin hydrochloride controlled-release tablet in the second hour to be 10% to 35%, the release degree to be 40% to 70% in the sixth hour and the release degree to be more than 80% in the twelfth hour.

Described are pharmaceutical compositions comprising bupropion, metformin, phentermine, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective amount of bupropion, metformin, and phentermine. In certain embodiments, an aforementioned method is practiced in conjunction or tandem with a medical procedure or the use of a medical device or both.

An antidiabetic pharmaceutical formulation is provided, especially adapted for treating Type II diabetes, which includes a combination of metformin and glipizide in a manner to control moisture in the formulation so that the glipizide does not hydrolyze, yet the metformin is compressible, if necessary. A method for treating diabetes is also provided employing the above formulation.

Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.

A slow-releasing capsule of compound fluamine pyrrolinone for treating diabetes is composed of the central slow-releasing fluamine microball or small tablet and the coated fast-releasing pyrrolinone layer. Its advantages are high curative effect and no toxic by-effect.

A slowly-releasing mellitin tablet is prepared from fluamine, excipient, adhesive and lubricant through drying at 40-70 deg.C for 4-6 hrs, pulverizing, sieving by 80-120 meshes, proportionally mixing, mixing with alcohol solution, granularating by 18-mesh sieving, drying at 40-60 deg.C for 2-4 hrs, mixing with lubricant, and tabletting. Its advantages are long half-life (0.9-2.6 hr), low dosage and low by-effect.